Paris, France – April 7, 2021

ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that Pierre Belichard, CEO, will present an overview of the Company and take part in 1-on-1 meetings with institutional investors at the following conferences:

• European Biotech Investor Days: April 7-8
• Jefferies Microbiome-based therapeutics Summit: April 22
• Jefferies Virtual Healthcare Conference: June 1-3

Enterome’s CBO, Anne Dagallier, will participate and take part in 1-on-1 meetings with potential business partners at the following conferences:

• Digestive Disease Week (DDW): May 21-23
• BIO International Convention: June 14-18

---

Download the press release (.pdf format)